Letter to the Editor

Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy

DOI: 10.4103/sajc.sajc_165_18

Dear Editor,

Carcinoma of the maxillary sinus is a rare malignancy.^[1,2] Due to this, there are limited prospective studies that have been reported. As the early stages of this malignancy remain asymptomatic, most patients get diagnosed in a locally advanced stage.^[1] Due

to its anatomical proximity to vital structures, surgical resection is a challenge, especially in locally advanced stages. However, surgical resection remains the cornerstone of management of this cancer.^[3] In a study done by Iyer *et al.* in resectable locally advanced maxillary sinus cancers, surgical resection was associated with a 5-year disease-specific survival of 71% versus 0% in chemoradiation arm ($P = 0.05$).^[4] However, in very locally advanced borderline resectable maxillary sinus carcinoma, upfront surgery is not possible. We had reported our initial results in 41 patients treated between 2008 and 2011 with induction chemotherapy in these tumors.^[5] In this letter, we report the long-term results of patients treated with this strategy.

(Continue on page 214...)

(Letter to the editor continue from page 213...)

Table 1: The impact of different factors on progression-free survival and overall survival

Variable	Hazard ratio	95% hazard ratio	P
Factors impacting PFS			
Type of local treatment received	0.608	0.112-3.304	0.564
Baseline BMI	1.898	0.709-5.086	0.202
Baseline serum albumin level	3.308	1.365-8.017	0.008
Baseline hemoglobin	0.564	0.227-1.401	0.217
Age	0.608	0.232-1.589	0.310
N stage	0.648	0.247-1.702	0.378
Resectable considered post-NACT in MDJC	1.867	0.527-6.608	0.333
Dose intensity of NACT	0.759	0.244-2.359	0.633
Type of regimen	1.296	0.552-3.044	0.551
Grade	5.145	1.302-20.329	0.019
Factors impacting OS			
Type of local treatment received	1.354	0.252-7.288	0.724
Baseline BMI	1.275	0.517-3.145	0.597
Baseline serum albumin level	3.193	1.270-8.026	0.014
Baseline hemoglobin	0.645	0.286-1.455	0.291
Age	0.497	0.195-1.265	0.142
N stage	0.810	0.323-2.032	0.654
Resectable considered post-NACT in MDJC	0.940	0.257-3.444	0.926
Dose intensity of NACT	0.765	0.274-2.138	0.609
Type of regimen	1.193	0.516-2.755	0.680
Grade	3.981	1.019-15.551	0.047

MDJC=Multidisciplinary joint clinic, PFS=Progression-free survival, OS=Overall survival, NACT=Neoadjuvant chemotherapy, BMI=Body mass index

Forty-one patients with locally advanced technically unresectable maxillary sinus carcinoma were treated with two cycles of induction chemotherapy. All patients had T4 disease. The induction chemotherapy consisted of either three-drug regimen of docetaxel, cisplatin, and 5-fluorouracil or two-drug regimen of taxane (docetaxel or paclitaxel) and platinum (cisplatin or carboplatin). The chemotherapy regimens received were TPF in 7 patients, docetaxel-platinum in 15 patients, and rest received paclitaxel-platinum. The median cycles received were 2. Postinduction regimen, the response rate was 39% (16 patients). These patients were then discussed in a multidisciplinary joint clinic. The further treatment these patients underwent were surgical resection followed by postoperative chemoradiation in 8 patients, radical chemoradiation in 21 patients, radical radiation in 1 patient, palliative radiation in 1 patient, palliative chemotherapy in 4 patients, and best supportive care in 6 patients.

R version 3.4.2 (R Foundation for Statistical Computing, Vienna, Austria) was used for analysis. Kaplan–Meier method was used for the estimation of progression-free survival (PFS) and overall survival (OS). Follow-up was calculated using reverse Kaplan–Meier method. Cox regression analysis was used to identify factors affecting PFS and OS. The median follow-up was 66.3 months. The 5-year progression-free survival rate and OS rate were 15.2% (95% confidence interval [CI] 3.2%–27.2%) and 16.9% (95% CI 4.9%–28.9%),

respectively. The factors which were independently associated with an improvement in PFS and OS were grade of tumor and serum albumin level [Table 1].

The outcomes of T4 carcinoma maxilla reported in the literature are poor.^[1] Even resected T4 maxillary sinus carcinomas have a 5-year OS between 20% and 36%.^[6-8] The outcomes of resectable carcinoma maxilla who are treated with chemoradiation are dismal.^[4] The 5-year disease-specific survival in these patients is 0%. Considering these outcomes, strategy of providing induction chemotherapy followed local treatment based on response seems reasonable. In view of the rarity of this malignancy, it is unlikely that a prospective randomized study would be conducted in this malignancy. Hence, we opine that, in view of the long-term results seen with induction therapy, induction followed by local treatment should be considered as an option in technically unresectable maxillary sinus carcinomas.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Sachin Babanrao Dhupal, Vijay M. Patil, Amit Joshi, Vanita Noronha, Arun Chandrasekharan, Prathamesh Pai¹, Kumar Prabhash

Departments of Medical Oncology and ¹Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
Correspondence to: Dr. Kumar Prabhash,
E-mail: kumarprabhastmh@gmail.com

References

1. Dubal PM, Bhojwani A, Patel TD, Zuckerman O, Baredes S, Liu JK, *et al.* Squamous cell carcinoma of the maxillary sinus: A population-based analysis. *Laryngoscope* 2016;126:399-404.
2. Gibson TN, McNaughton DP, Hanchard B. Sinonasal malignancies: Incidence and histological distribution in Jamaica, 1973-2007. *Cancer Causes Control* 2017;28:1219-25.
3. Al-Jhani AS, Al-Rajhi NM, El-Sebaie MM, Nooh NS, Mahasen ZZ, Al-Amro AS, *et al.* Maxillary sinus carcinoma. Natural history and outcome. *Saudi Med J* 2004;25:929-33.
4. Iyer NG, Tan DS, Tan VK, Wang W, Hwang J, Tan NC, *et al.* Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. *Cancer* 2015;121:1599-607.
5. Noronha V, Patil VM, Joshi A, Krishna MV, Dhupal S, Juvekar S, *et al.* Induction chemotherapy in technically unresectable locally advanced carcinoma of maxillary sinus. *Chemother Res Pract* 2014;2014:487872.
6. Hayashi T, Nonaka S, Bando N, Kobayashi Y, Imada M, Harabuchi Y, *et al.* Treatment outcome of maxillary sinus squamous cell carcinoma. *Cancer* 2001;92:1495-503.
7. Santos MR, Servato JP, Cardoso SV, de Faria PR, Eisenberg AL, Dias FL, *et al.* Squamous cell carcinoma at maxillary sinus: Clinicopathologic data in a single Brazilian institution with review of literature. *Int J Clin Exp Pathol* 2014;7:8823-32.
8. Waldron JN, O'Sullivan B, Gullane P, Witterick IJ, Liu FF, Payne D, *et al.* Carcinoma of the maxillary antrum: A retrospective analysis of 110 cases. *Radiother Oncol* 2000;57:167-73.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Dhupal SB, Patil VM, Joshi A, Noronha V, Chandrasekharan A, Pai P, *et al.* Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy. *South Asian J Cancer* 2018;7:213-4.

© 2018 The South Asian Journal of Cancer | Published by Wolters Kluwer - Medknow